Tiziana Life Sciences Ltd
Biotech firm developing immunotherapies for neurodegenerative diseases like MS and Alzheimer's.
TLSA | NDAQ
Overview
Corporate Details
- ISIN(s):
- BMG889121031
- LEI:
- Country:
- United States of America
- Address:
- 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON, ENGLAND
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company developing transformative immunotherapies, with a primary focus on neurodegenerative and neuroinflammatory diseases. The company's lead candidate, intranasal Foralumab (TZLS-401), is a fully human anti-CD3 monoclonal antibody being evaluated in clinical trials for conditions such as Non-Active Secondary Progressive Multiple Sclerosis (SPMS), Alzheimer's Disease, and ALS. Tiziana's pipeline also includes an anti-IL-6R monoclonal antibody (TZLS-501) for lung diseases and Milciclib for oncology. The company's mission is to leverage innovative drug delivery technologies to create breakthrough therapies for patients with unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tiziana Life Sciences Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tiziana Life Sciences Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tiziana Life Sciences Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
